Table 3 Changes measured by OCT and ICGA in eyes at the 12-month follow-up
From: Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
Number of eyes (%) | Morphological changes |
|---|---|
43 (60.6%) | Subretinal fluids absorbed |
39 (55.7%) | PED resolved |
15 (18.8%) | Complete regression of polyps |
22 (27.5%) | Reduction in polyps |